Placebo solution for injection

DRUG2 trials

Sponsors

Anaptysbio Inc., Novartis Pharmaceuticals

Conditions

Atopic DermatitisChronic Spontaneous Urticaria (CSU)

Phase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

CompletedCTIS2023-503522-40-01

Anaptysbio Inc.Atopic Dermatitis

Start: 2024-04-10End: 2024-12-11Target: 84Updated: 2024-10-22

Phase 3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

RecruitingNCT06868212

Novartis PharmaceuticalsChronic Spontaneous Urticaria (CSU)

Start: 2025-07-11End: 2027-05-17Target: 400Updated: 2026-03-11

Related Papers

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)

Dermatology and Therapy2026-03-19